Mindmed announces first patient dosed in phase 2b trial of mm-120 in generalized anxiety disorder

New york , aug. 25, 2022 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed) (the "company" or "mindmed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced first patient dosing in its phase 2b dose-optimization trial of mm-120, a pharmaceutically optimized form of lysergic acid diethylamide (lsd), for the treatment of generalized anxiety disorder (gad). "the initiation of our phase 2b clinical trial, the largest well-controlled clinical trial of lsd ever conducted, represents a major milestone for mindmed and for the many patients suffering from gad," said robert barrow, chief executive officer and director of mindmed.
MNMD Ratings Summary
MNMD Quant Ranking